U.S. markets open in 3 hours 30 minutes

Gilead Sciences, Inc. (GILD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
60.79+0.12 (+0.20%)
At close: 4:00PM EDT

60.61 -0.18 (-0.30%)
Before hours: 5:55AM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close60.67
Open63.38
Bid60.70 x 1200
Ask0.00 x 1200
Day's Range60.76 - 63.64
52 Week Range59.65 - 85.97
Volume30,965,444
Avg. Volume9,647,715
Market Cap76.214B
Beta (5Y Monthly)0.57
PE Ratio (TTM)N/A
EPS (TTM)-0.20
Earnings DateOct 28, 2020
Forward Dividend & Yield2.72 (4.47%)
Ex-Dividend DateSep 14, 2020
1y Target Est78.42
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
19% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 2 Coronavirus Stocks to Avoid This Month
    Motley Fool

    2 Coronavirus Stocks to Avoid This Month

    Inovio Pharmaceuticals (NASDAQ: INO) and Gilead Sciences (NASDAQ: GILD) are major competitors in the growing market for coronavirus products, making both tantalizing stock picks. Inovio's stock has soared this year thanks to its INO-4800 coronavirus vaccine project, which has so far proven effective at producing immunity in primates. In contrast, Gilead's stock has consistently struggled despite the commercialization of its antiviral drug, remdesivir, which may be effective at helping patients recover from COVID-19.

  • Barrons.com

    Remdesivir Gets FDA Approval. What It Means for Gilead Stock and Vaccine Makers.

    Until vaccines end the Covid pandemic, analysts expect billions of dollars in annual sales for treatments and other remedies.

  • 4 Top Stock Trades for Monday: TWLO, SNAP, SPAQ, GILD
    InvestorPlace

    4 Top Stock Trades for Monday: TWLO, SNAP, SPAQ, GILD

    It was a back-and-forth trading session on Friday — what else is new — that ultimately led a slight rally on Wall Street. With that in mind, let’s look at a few top stock trades for next week.  Top Stock Trades for Monday No. 1: Twilio (TWLO) Click to EnlargeSource: Chart courtesy of StockCharts.com Twilio (NYSE:TWLO) is set to report earnings on Monday, Oct. 26. After breaking out to new highs near $340, shares have pulled back. Is it enough to warrant a post-earnings rally? If earnings weren’t around the corner, this dip into support would look pretty attractive. The prior highs near $280 to $285 held as support, as Twilio is now rallying back over $300.InvestorPlace - Stock Market News, Stock Advice & Trading Tips On the upside, bulls will be looking for a close above $340. Above that could put the 461.8% extension (from the March low to the preceding 2020 high) in play at $368. 7 Airline Stocks to Buy on Pelosi Stimulus Hopes On the downside, though, a close below $280 would put the 100-day and 50-day moving averages on the table. Below that, and $220 could be on deck. Top Stock Trades for Monday No. 2: Snap (SNAP) Click to EnlargeSource: Chart courtesy of StockCharts.com I covered Snap (NYSE:SNAP) earlier in the week after its monstrous earnings move. That rally was met by selling at the 261.8% extension. On a move over that mark, I said investors should look for a test of the three-times range extension at near $43.50. Almost there now and investors are wondering what to do with their long position. First, pat yourself on the back. Second, consider how to proceed. Some may want to fish for a full test of the three-times range, followed by a possible move to $50. Others may consider taking some profits here and riding it higher. A few investors may even consider parking a daily stop just below the 261.8% extension. This key level has been relevant all week and a close below this mark would be bad news. Either way, there are multiple ways to proceed from this point forward. No matter what risk management principles investors implement, many will be looking to buy on the dip. In that case, consider waiting for an eventual test of the 10-day moving average. Top Trades for Monday No. 3: Spartan Energy Acquisition (SPAQ) Click to EnlargeSource: Chart courtesy of StockCharts.com We also looked at Spartan Energy Acquisition (NYSE:SPAQ) recently. In that assessment, I said bulls needed to reclaim $14 to regain control and that a move below $12.50 support would put the 200-day moving average in play. Earlier this week, SPAQ broke decisively below $12.50. On Thursday, it broke aggressively below the 200-day moving average. Perhaps aggressive bulls can justify a dip buy now, looking for a rebound back to $11, then the 200-day moving average. 4 Top Dividend Stocks That’ll Pay You Better Than 'Exciting Trailblazers' However, a close below Friday’s low will not be a good look. That said, shares are down in six of the least seven sessions, and while it’s a risky setup, SPAQ stock looks due for a bounce. Top Stock Trades for Monday No. 4: Gilead Sciences (GILD) Click to EnlargeSource: Chart courtesy of StockCharts.com Gilead Sciences (NASDAQ:GILD) continues to trade like crap. After breaking to new 2020 lows earlier this week, shares popped on Friday morning. However, those gains couldn’t be maintained, as downtrend resistance (blue line) and the 50-day moving average rejected the stock. Now what? Below $61, and the monthly lows are in play. If broken, see if the stock quickly reclaims the $60 level — known as a “look below and fail” setup. In any case, bulls need to see shares close above the 50-day moving average to get any sort of sustained rally to the upside. On the downside, a break of $60 could put the $56 to $58 area in play, which has been multi-year support. On the date of publication, Bret Kenwell held a long position in TWLO. Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company The post 4 Top Stock Trades for Monday: TWLO, SNAP, SPAQ, GILD appeared first on InvestorPlace.